Patent intelligence · US
US 6689782
Fungal efflux pump inhibitors
Fungal efflux pump inhibitors
Patent details — US 6689782
- Jurisdiction
- US
- Status
- expired
- Grant date
- Feb 10, 2004
- Expiration
- Feb 5, 2024
- Applicant
- Essential Therapeutics, Inc.
- Claims
- 37
- CPC classes
- A61K, A61K31/33, A61K31/495, A61K31/517
Quick answer
US 6689782 (Fungal efflux pump inhibitors) is held by Essential Therapeutics, Inc.. Status: expired. Granted Feb 10, 2004. Expires Feb 5, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Essential Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 37
- CPC classes
- A61K, A61K31/33, A61K31/495, A61K31/517, A61K45/06
More from Essential Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 6689782?
US 6689782 (Fungal efflux pump inhibitors) is held by Essential Therapeutics, Inc.. Status: expired. Granted Feb 10, 2004. Expires Feb 5, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6689782?
Essential Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 6689782 expire?
Our index shows an expiration date of Feb 5, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.